Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Dec 1;89(23):11189–11193. doi: 10.1073/pnas.89.23.11189

Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate.

C F Scott 1, R W Colman 1
PMCID: PMC50515  PMID: 1454798

Abstract

The intrinsic pathway of blood coagulation is activated when factor XIa, one of the three contact-system enzymes, is generated and then activates factor IX. Factor XI has been shown to be efficiently activated in vitro by surface-bound factor XIIa after factor XI is transported to the surface by its cofactor, high molecular weight kininogen (HK). However, individuals lacking any of the three contact-system proteins--namely, factor XII, prekallikrein, and HK--do not suffer from bleeding abnormalities. This mystery has led several investigators to search for an "alternate" activation pathway for factor XI. Recently, factor XI has been reported to be autoactivated on the soluble "surface" dextran sulfate, and thrombin was shown to accelerate the autoactivation. However, it was also reported that HK, the cofactor for factor XIIa-mediated activation of factor XI, actually diminishes the thrombin-catalyzed activation rate of factor XI. Nonetheless, it was suggested that thrombin was a more efficient activator than factor XIIa. In this report we investigated the effect of fibrinogen, the major coagulation protein in plasma, on the activation rate of factor XI. Fibrinogen, the preferred substrate for thrombin in plasma, virtually prevented autoactivation of factor XI as well as the thrombin-mediated activation of factor XI, while having no effect on factor XIIa-catalyzed activation. HK dramatically curtailed the autoactivation of factor XI in addition to the thrombin-mediated activation. These data indicate that factor XI would not be autoactivated in a plasma environment, and thrombin would, therefore, be unlikely to potentiate the activation. We believe that the "missing pathway" for factor XI activation remains an enigma that warrants further investigation.

Full text

PDF
11189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cochrane C. G., Griffin J. H. Molecular assembly in the contact phase of the Hageman factor system. Am J Med. 1979 Oct;67(4):657–664. doi: 10.1016/0002-9343(79)90253-5. [DOI] [PubMed] [Google Scholar]
  2. Cochrane C. G., Revak S. D., Wuepper K. D. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med. 1973 Dec 1;138(6):1564–1583. doi: 10.1084/jem.138.6.1564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Colman R. W., Bagdasarian A., Talamo R. C., Scott C. F., Seavey M., Guimaraes J. A., Pierce J. V., Kaplan A. P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest. 1975 Dec;56(6):1650–1662. doi: 10.1172/JCI108247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colman R. W., Mattler L., Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest. 1969 Jan;48(1):23–32. doi: 10.1172/JCI105971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fenton J. W., 2nd, Fasco M. J., Stackrow A. B. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977 Jun 10;252(11):3587–3598. [PubMed] [Google Scholar]
  6. Gailani D., Broze G. J., Jr Factor XI activation in a revised model of blood coagulation. Science. 1991 Aug 23;253(5022):909–912. doi: 10.1126/science.1652157. [DOI] [PubMed] [Google Scholar]
  7. Greenberg C. S., Miraglia C. C., Rickles F. R., Shuman M. A. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest. 1985 May;75(5):1463–1470. doi: 10.1172/JCI111849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hathaway W. E., Belhasen L. P., Hathaway H. S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood. 1965 Nov;26(5):521–532. [PubMed] [Google Scholar]
  9. Hogg P. J., Jackson C. M. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates. J Biol Chem. 1990 Jan 5;265(1):248–255. [PubMed] [Google Scholar]
  10. Kaplan A. P., Austen K. F. A pre-albumin activator of prekallikrein. J Immunol. 1970 Oct;105(4):802–811. [PubMed] [Google Scholar]
  11. LORAND L. 'Fibrino-peptide'; new aspects of the fibrinogen-fibrin transformation. Nature. 1951 Jun 16;167(4259):992–993. doi: 10.1038/167992a0. [DOI] [PubMed] [Google Scholar]
  12. Lacombe M. J., Varet B., Levy J. P. A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): case report and coagulation studies. Blood. 1975 Nov;46(5):761–768. [PubMed] [Google Scholar]
  13. Mandle R. J., Colman R. W., Kaplan A. P. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976 Nov;73(11):4179–4183. doi: 10.1073/pnas.73.11.4179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Naito K., Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem. 1991 Apr 25;266(12):7353–7358. [PubMed] [Google Scholar]
  15. Osterud B., Bouma B. N., Griffin J. H. Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem. 1978 Sep 10;253(17):5946–5951. [PubMed] [Google Scholar]
  16. Osterud B., Rapaport S. I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5260–5264. doi: 10.1073/pnas.74.12.5260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. RATNOFF O. D., COLOPY J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. 1955 Apr;34(4):602–613. doi: 10.1172/JCI103109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. RATNOFF O. D., DAVIE E. W., MALLETT D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest. 1961 May;40:803–819. doi: 10.1172/JCI104314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Revak S. D., Cochrane C. G., Griffin J. H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest. 1977 Jun;59(6):1167–1175. doi: 10.1172/JCI108741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saito H., Goodnough L. T., Soria J., Soria C., Aznar J., España F. Heterogeneity of human prekallikrein deficiency (Fletcher trait): evidence that five of 18 cases are positive for cross-reacting material. N Engl J Med. 1981 Oct 15;305(16):910–914. doi: 10.1056/NEJM198110153051602. [DOI] [PubMed] [Google Scholar]
  21. Saito H., Ratnoff O. D., Waldmann R., Abraham J. P. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). J Clin Invest. 1975 May;55(5):1082–1089. doi: 10.1172/JCI108009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schiffman S., Lee P. Partial purification and characterization of contact activation cofactor. J Clin Invest. 1975 Nov;56(5):1082–1092. doi: 10.1172/JCI108182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Scott C. F., Mentzer R. L., Budzynski A. Z., Colman R. W. Human factor XIa cleaves fibrinogen: effects on structure and function. Arch Biochem Biophys. 1986 Sep;249(2):480–488. doi: 10.1016/0003-9861(86)90025-1. [DOI] [PubMed] [Google Scholar]
  24. Scott C. F., Silver L. D., Purdon A. D., Colman R. W. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem. 1985 Sep 5;260(19):10856–10863. [PubMed] [Google Scholar]
  25. Scott C. F., Silver L. D., Schapira M., Colman R. W. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest. 1984 Apr;73(4):954–962. doi: 10.1172/JCI111319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Scott C. F., Sinha D., Seaman F. S., Walsh P. N., Colman R. W. Amidolytic assay of human factor XI in plasma: comparison with a coagulant assay and a new rapid radioimmunoassay. Blood. 1984 Jan;63(1):42–50. [PubMed] [Google Scholar]
  27. Thompson R. E., Mandle R., Jr, Kaplan A. P. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest. 1977 Dec;60(6):1376–1380. doi: 10.1172/JCI108898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Weiss A. S., Gallin J. I., Kaplan A. P. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest. 1974 Feb;53(2):622–633. doi: 10.1172/JCI107597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wuepper K. D. Prekallikrein deficiency in man. J Exp Med. 1973 Dec 1;138(6):1345–1355. doi: 10.1084/jem.138.6.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES